P/E
Price to Earnings

21.7
Current
18.9
Median
21.4
Industry
Higher than median
Higher than industry value

The Price to Earnings (P/E) ratio shows how much investors are willing to pay for each dollar of a company’s earnings. It’s calculated by dividing the company’s market value by its net income.

P/E
21.7
=
Market Cap
9.8B EUR
/
Net Income
448m EUR
All Countries
Close
Earnings Growth PEG
FR
Ipsen SA
PAR:IPN
Average P/E: 24.3
21.7
42%
0.5
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.8
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
CH
Novartis AG
SIX:NOVN
18.8
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
10.4
2-Years Forward
P/E
10.5
3-Years Forward
P/E
10